Lanean...
JAK2 inhibitors: are they the solution?
The discovery of the JAK2V617F mutation in patients with Philadelphia-negative myeloproliferative neoplasms (Ph-negative MPNs) started the era of targeted therapy for these diseases. Until now, patients had few treatment options available, usually restricted to hydroxyurea, interferon preparations,...
Gorde:
| Argitaratua izan da: | Clin Lymphoma Myeloma Leuk |
|---|---|
| Egile Nagusiak: | , |
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
2011
|
| Gaiak: | |
| Sarrera elektronikoa: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4445410/ https://ncbi.nlm.nih.gov/pubmed/22035745 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.clml.2011.02.007 |
| Etiketak: |
Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|